RETRANSMISSION: Goldman Small Cap Research Publishes New Research Report on Sigyn Therapeutics Inc.
Sigyn Therapeutics (OTCQB:SIGY) has been featured in a new research report by Goldman Small Cap Research, highlighting the company's development of next-generation blood purification therapies. The company's flagship product, Sigyn Therapy鈩�, is a first-in-class device targeting severe inflammatory disorders, primarily sepsis and end stage renal disease (ESRD).
The device has demonstrated capability to reduce bacterial toxins, inflammatory cytokines, hepatic toxins, and infectious viral pathogens from human blood plasma. Additionally, Sigyn is developing medical devices to enhance cancer drug treatment effectiveness.
According to the research report, Sigyn plans to submit multiple Breakthrough Device submissions this year and expects to commence an ESRD feasibility study within the next 12 months. The study could yield data within 6 months of completion. Goldman Small Cap Research has issued a price target for SIGY, suggesting the company is currently undervalued compared to peers.
Sigyn Therapeutics (OTCQB:SIGY) 猫 stata oggetto di un nuovo rapporto di ricerca da parte di Goldman Small Cap Research, che mette in luce lo sviluppo da parte dell'azienda di terapie di purificazione del sangue di nuova generazione. Il prodotto di punta dell'azienda, Sigyn Therapy鈩�, 猫 un dispositivo innovativo che si rivolge a gravi disturbi infiammatori, in particolare sepsi e insufficienza renale terminale (ESRD).
Il dispositivo ha dimostrato la capacit脿 di ridurre tossine batteriche, citochine infiammatorie, tossine epatiche e agenti patogeni virali infettivi dal plasma sanguigno umano. Inoltre, Sigyn sta sviluppando dispositivi medici per migliorare l'efficacia dei trattamenti farmacologici contro il cancro.
Secondo il rapporto di ricerca, Sigyn prevede di presentare quest'anno pi霉 richieste per dispositivi innovativi (Breakthrough Device) e si aspetta di avviare uno studio di fattibilit脿 sull'ESRD entro i prossimi 12 mesi. Lo studio potrebbe fornire dati entro 6 mesi dal completamento. Goldman Small Cap Research ha fissato un prezzo obiettivo per SIGY, suggerendo che l'azienda 猫 attualmente sottovalutata rispetto ai concorrenti.
Sigyn Therapeutics (OTCQB:SIGY) ha sido destacada en un nuevo informe de investigaci贸n de Goldman Small Cap Research, que resalta el desarrollo por parte de la compa帽铆a de terapias de purificaci贸n sangu铆nea de pr贸xima generaci贸n. El producto principal de la empresa, Sigyn Therapy鈩�, es un dispositivo pionero que se enfoca en trastornos inflamatorios severos, principalmente sepsis y enfermedad renal terminal (ESRD).
El dispositivo ha demostrado la capacidad de reducir toxinas bacterianas, citoquinas inflamatorias, toxinas hep谩ticas y pat贸genos virales infecciosos del plasma sangu铆neo humano. Adem谩s, Sigyn est谩 desarrollando dispositivos m茅dicos para mejorar la efectividad del tratamiento farmacol贸gico contra el c谩ncer.
Seg煤n el informe de investigaci贸n, Sigyn planea presentar m煤ltiples solicitudes de Dispositivo Innovador (Breakthrough Device) este a帽o y espera comenzar un estudio de viabilidad para ESRD en los pr贸ximos 12 meses. El estudio podr铆a proporcionar datos dentro de los 6 meses posteriores a su finalizaci贸n. Goldman Small Cap Research ha establecido un precio objetivo para SIGY, sugiriendo que la compa帽铆a est谩 actualmente subvalorada en comparaci贸n con sus pares.
Sigyn Therapeutics (OTCQB:SIGY)電� Goldman Small Cap Research鞚� 靸堧鞖� 鞐瓣惮 氤搓碃靹滌棎 靻岅皽霅橃柎, 彀劯雽� 順堨暋 鞝曧檾 旃橂氩� 臧滊皽鞚� 臧曥“頄堨姷雼堧嫟. 須岇偓鞚� 雽�響� 鞝滍拡鞚� Sigyn Therapy鈩�電� 欷戩 鞐检 歆堩櫂, 欤茧 韺槇歃� 氚� 毵愱赴 鞁犾灔 歆堩櫂(ESRD)鞚� 雽�靸侅溂搿� 頃橂姅 順侅嫚鞝侅澑 鞛レ箻鞛呺媹雼�.
鞚� 鞛レ箻電� 鞚戈皠 順堨灔 雮挫潣 氚曧厡毽晞 霃呾唽, 鞐检靹� 靷澊韱犾勾鞚�, 臧� 霃呾唽 氚� 臧愳椉靹� 氚旍澊霟姢 氤戩洂觳措ゼ 臧愳唽鞁滍偆電� 電ル牓鞚� 鞛呾頄堨姷雼堧嫟. 霕愴暅 Sigyn鞚� 鞎� 旃橂鞝滌潣 須姤鞚� 頄レ儊鞁滍偆旮� 鞙勴暅 鞚橂旮瓣赴霃� 臧滊皽 欷戩瀰雼堧嫟.
鞐瓣惮 氤搓碃靹滌棎 霐半ゴ氅�, Sigyn鞚� 鞓暣 雼れ垬鞚� 順侅嫚 鞚橂旮瓣赴(Breakthrough Device) 鞝滌稖鞚� 瓿勴殟頃橁碃 鞛堨溂氅�, 頄ロ泟 12臧滌洈 雮挫棎 ESRD鞐� 雽�頃� 韮�雼轨劚 鞐瓣惮毳� 鞁滌瀾頃� 鞓堨爼鞛呺媹雼�. 鞚� 鞐瓣惮電� 鞕勲 頉� 6臧滌洈 雮挫棎 雿办澊韯半ゼ 鞝滉车頃� 靾� 鞛堨姷雼堧嫟. Goldman Small Cap Research電� SIGY鞐� 雽�頃� 氇╉憸 欤缄皜毳� 鞝滌嫓頃橂┌, 順勳灛 霃欖 旮办梾 雽�牍� 鞝�韽夑皜霅橃柎 鞛堧嫟瓿� 韽夑皜頄堨姷雼堧嫟.
Sigyn Therapeutics (OTCQB:SIGY) a 茅t茅 mis en avant dans un nouveau rapport de recherche de Goldman Small Cap Research, soulignant le d茅veloppement par l'entreprise de th茅rapies de purification sanguine de nouvelle g茅n茅ration. Le produit phare de la soci茅t茅, Sigyn Therapy鈩�, est un dispositif innovant ciblant les troubles inflammatoires s茅v猫res, principalement la sepsie et l'insuffisance r茅nale terminale (ESRD).
Le dispositif a d茅montr茅 sa capacit茅 脿 r茅duire les toxines bact茅riennes, les cytokines inflammatoires, les toxines h茅patiques et les agents pathog猫nes viraux infectieux dans le plasma sanguin humain. De plus, Sigyn d茅veloppe des dispositifs m茅dicaux pour am茅liorer l'efficacit茅 des traitements m茅dicamenteux contre le cancer.
Selon le rapport de recherche, Sigyn pr茅voit de soumettre plusieurs dossiers de dispositifs r茅volutionnaires (Breakthrough Device) cette ann茅e et s'attend 脿 commencer une 茅tude de faisabilit茅 sur l'ESRD dans les 12 prochains mois. L'茅tude pourrait fournir des donn茅es dans les 6 mois suivant son ach猫vement. Goldman Small Cap Research a fix茅 un objectif de cours pour SIGY, sugg茅rant que la soci茅t茅 est actuellement sous-茅valu茅e par rapport 脿 ses pairs.
Sigyn Therapeutics (OTCQB:SIGY) wurde in einem neuen Forschungsbericht von Goldman Small Cap Research vorgestellt, der die Entwicklung von Therapien zur Blutreinigung der n盲chsten Generation durch das Unternehmen hervorhebt. Das Flaggschiff-Produkt des Unternehmens, Sigyn Therapy鈩�, ist ein neuartiges Ger盲t, das auf schwere entz眉ndliche Erkrankungen abzielt, insbesondere Sepsis und Endstadium der Nierenerkrankung (ESRD).
Das Ger盲t hat gezeigt, dass es in der Lage ist, bakterielle Toxine, entz眉ndliche Zytokine, Lebertoxine und infekti枚se virale Krankheitserreger aus menschlichem Blutplasma zu reduzieren. Dar眉ber hinaus entwickelt Sigyn medizinische Ger盲te, um die Wirksamkeit von Krebsmedikamenten zu verbessern.
Dem Forschungsbericht zufolge plant Sigyn, in diesem Jahr mehrere Antr盲ge f眉r Breakthrough Devices einzureichen und erwartet, innerhalb der n盲chsten 12 Monate eine Machbarkeitsstudie f眉r ESRD zu starten. Die Studie k枚nnte innerhalb von 6 Monaten nach Abschluss Daten liefern. Goldman Small Cap Research hat ein Kursziel f眉r SIGY ausgegeben und deutet darauf hin, dass das Unternehmen derzeit im Vergleich zu Wettbewerbern unterbewertet ist.
- None.
- No FDA-approved treatments yet
- Currently trading on OTCQB market rather than major exchange
- Feasibility study results won't be available for at least 18 months
Underfollowed Innovator to Enjoy Profile Raise
BALTIMORE, MD / / July 1, 2025 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a new research report on Sigyn Therapeutics Inc. (OTCQB:SIGY), a developer of next-generation blood purification therapies to address life-threatening conditions that carry no FDA-approved treatments. The Goldman report carries a price target. To view the new research report, along with disclosures and disclaimers, or to download the report in its entirety, please visit: .
Sigyn Therapeutics, Inc. is developing next-generation blood purification therapies to address life-threatening conditions with no FDA-approved treatments. Sigyn Therapy鈩� is a first-in-class device to address severe inflammatory disorders. Its primary targeted conditions are sepsis and end stage renal disease. The flagship platform therapy has been demonstrated to reduce the presence of bacterial toxins (including endotoxin), inflammatory cytokines, hepatic toxins, and infectious viral pathogens from human blood plasma. The Company is also developing medical devices to optimize the benefit of drugs to treat cancer.
In the Opportunity Research report, analyst Rob Goldman reviews this undervalued and underfollowed innovator including upcoming milestones and events, clinical achievements, unique opportunities in multi-billion-dollar indications, and a price target for SIGY.
SIGY: Game Changing Approach
Goldman commented, "Sigyn is poised to change the way acute, life-threatening inflammatory conditions induced by endotoxemia and other concurrent inflammation. Many of these conditions have no approved therapy and represent billions in market size. The primary targeted conditions include end stage renal disease and sepsis, the #1 cause of deaths in hospitals worldwide. The Company also has a deep oncology portfolio."
Potential Near Term Valuation-Raising Milestones Ahead
"Sigyn has reported favorable in vitro results and is poised to submit multiple Breakthrough Device submissions this year. The Company could be awarded these designations in the coming quarter," noted Goldman. "A planned ESRD feasibility study should commence in the next 12 months. Data could be derived from this trial within 6 months following the end of the study."
Upcoming Events Could Raise Profile
"Our six-month price target reflects both the current undervalued and underfollowed status of Sigyn versus peers, but also the value of future milestones. In our view, Sigyn's primary platform offers valuable, hidden features which could serve as a valuation driver. Looking ahead, future milestones could eventually lead to an M&A event," concluded Goldman.
About Goldman Small Cap Research: Founded in 2009by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and microcap stock research reports, articles, stock market blogs, and popular investment newsletters.
Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.
This press release contains excerpts of our most recently published company report on Sigyn Therapeutics Inc. ("The Company"). The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research relied solely upon information derived from Sigyn Therapeutics Inc. The information includes authorized press releases or legal disclosures made in their filings with the U.S. Securities and Exchange Commission .
Separate from the factual content of our update about the Company, we may from time to time include our own opinions about the Company, its business, markets, and opportunities. Any opinions we may offer about the Company are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice. Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results.
A Goldman Small Cap Research report, update, newsletter, article, trading alert, corporate profile, sector or industry snapshot, podcast interview, or press release is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other regulatory agency. To download this research report, visit . Goldman Small Cap Research did not receive any compensation for this report. In 2021, Goldman Small Cap Research was compensated by the Company in the amount of
Goldman Small Cap Research
Rob Goldman, Analyst
410-800.7980
[email protected]
SOURCE: Goldman Small Cap Research
View the original on ACCESS Newswire
FAQ
What is Sigyn Therapeutics' (SIGY) main product?
What conditions does Sigyn Therapeutics (SIGY) target with its blood purification therapy?
What are the upcoming milestones for Sigyn Therapeutics (SIGY)?
What has Sigyn Therapy demonstrated in testing so far?
When will Sigyn Therapeutics (SIGY) begin its ESRD feasibility study?
